Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Dr Shannon Thomas

TIAs and Carotid Stenosis

Dr Ginni Mansberg

Low libido - What is it & How is it Managed?

Dr Rupert Hinds

Functional Gastrointestinal Disorders in Infants – Practical Advice for HCPs

A/Prof Michael Woodward AM

Using the New RSV Vaccine in Practice

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

30 April 2024

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD